ライソゾーム病治療市場- 世界の産業規模、シェア、動向、機会、予測、治療タイプ別、疾患タイプ別、地域別、競合別、2020～2030年

ライソゾーム病治療の世界市場は2024年に46億1,000万米ドルと評価され、2030年にはCAGR 4.55％で60億3,000万米ドルに達すると予測されます。

世界のライソゾーム病（LSD）治療市場は、ライソゾーム内の酵素欠損に起因する希少遺伝性疾患の有病率の上昇により、著しい成長を遂げています。ゴーシェ病、ファブリー病、ポンペ病、ムコ多糖症を含むライソゾーム病は、しばしば重篤で進行性の生命を脅かす病態を引き起こし、効果的な治療法に対する強い需要を生み出しています。酵素補充療法（ERT）は治療の要となっており、正常な酵素機能を回復させ、患者の予後を改善するのに役立っています。遺伝子治療や基質減少療法も、根本的な遺伝的欠陥に対処し、疾患の進行を遅らせる革新的なアプローチとして台頭してきています。早期診断と治療の選択肢に関するヘルスケアプロバイダや患者の意識の高まりが、先進的な治療法の採用をさらに後押ししています。製薬企業やバイオテクノロジー企業による研究開発努力の増加は、承認された治療法のポートフォリオを拡大し、患者に多くの選択肢を提供し、長期的な疾患管理を改善しています。

市場動向は、精密医療と個別化治療アプローチへのシフトを示しています。遺伝子検査、分子診断、次世代シーケンスの進歩により、ライソゾーム障害の早期かつ正確な診断が可能になりつつあり、これは効果的な治療に不可欠です。企業は遺伝子治療プラットフォームを活用し、長時間作用型で治癒の可能性のあるソリューションを開発することで、通院頻度を減らし、患者のQOLを向上させています。また、酵素補充と補助的治療を統合して有効性を高める併用療法への注目も高まっています。患者モニタリング、遠隔医療相談、アドヒアランス追跡のためのデジタルヘルスプラットフォームの統合は、臨床医が患者の反応に基づいてリアルタイムで治療を調整できるようにし、疾病管理に変革をもたらしつつあります。製薬企業と研究機関の戦略的提携や協力関係がイノベーションを促進し、臨床検査を加速させ、新規治療へのアクセスを拡大しています。

主要市場促進要因

ライソゾーム障害の有病率の上昇

主要市場課題

治療費の高騰

主要市場動向

遺伝子治療とRNAベース治療の台頭

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界のライソゾーム病治療市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 治療タイプ別（酵素補充療法（ベラグルセラーゼアルファ、アルグルコシダーゼアルファ（マイオザイム/ルミザイム）、イデュルスルファーゼ（エラプレーゼ）、イミグルセラーゼ（セレザイム））、その他（基質還元療法、その他））
  • 疾患タイプ別（ゴーシェ病、ムコ多糖症、ポンペ病、ファブリー病、その他）
  • 企業別（2024年）
  • 地域別
• 市場マップ

第6章 北米のライソゾーム病治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第7章 欧州のライソゾーム病治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • 英国
  • イタリア
  • スペイン

第8章 アジア太平洋のライソゾーム病治療市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋：国別分析
  • 中国
  • インド
  • 韓国
  • 日本
  • オーストラリア

第9章 南米のライソゾーム病治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカのライソゾーム病治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 合併と買収
• 製品上市

第13章 混乱：紛争、パンデミック、貿易障壁

第14章 ポーターのファイブフォース分析

• 産業内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第15章 競合情勢

• Pfizer Inc.
• Takeda Pharmaceutical Company Limited
• Sanofi S.A.
• BioMarin Pharmaceutical Inc.
• Johnson & Johnson（Actelion Pharmaceuticals Ltd）
• Amicus Therapeutics, Inc.
• Alexion Pharmaceuticals, Inc.
• Sigilon Therapeutics, Inc.
• Orphazyme A/S
• Ultragenyx Pharmaceutical Inc.

第16章 戦略的提言

第17章 調査会社について・免責事項

The Global Lysosomal Storage Disease Treatment Market was valued at USD 4.61 Billion in 2024 and is expected to reach USD 6.03 Billion by 2030 with a CAGR of 4.55%. The Global Lysosomal Storage Disease (LSD) Treatment Market is witnessing significant growth due to the rising prevalence of rare genetic disorders that result from enzyme deficiencies within lysosomes. Lysosomal storage diseases, including Gaucher disease, Fabry disease, Pompe disease, and mucopolysaccharidoses, often lead to severe, progressive, and life-threatening conditions, creating strong demand for effective therapies. Enzyme replacement therapies (ERTs) have become a cornerstone of treatment, helping restore normal enzyme function and improve patient outcomes. Gene therapy and substrate reduction therapy are also emerging as innovative approaches to address underlying genetic defects and slow disease progression. Growing awareness among healthcare providers and patients regarding early diagnosis and treatment options is further driving the adoption of advanced therapies. Increasing research and development efforts by pharmaceutical and biotechnology companies are expanding the portfolio of approved treatments, providing more choices to patients and improving long-term disease management.

Market trends indicate a shift toward precision medicine and personalized therapy approaches. Advances in genetic testing, molecular diagnostics, and next-generation sequencing are enabling early and accurate diagnosis of lysosomal storage disorders, which is critical for effective treatment. Companies are leveraging gene therapy platforms to develop long-acting and potentially curative solutions, reducing the frequency of hospital visits and improving patient quality of life. There is also an increasing focus on combination therapies that integrate enzyme replacement with adjunctive treatments to enhance efficacy. Integration of digital health platforms for patient monitoring, telemedicine consultations, and adherence tracking is transforming disease management, allowing clinicians to adjust therapy in real time based on patient response. Strategic collaborations and partnerships between pharmaceutical companies and research institutions are fueling innovation, accelerating clinical trials, and expanding access to novel therapies.

Key Market Drivers

Rising Prevalence of Lysosomal Storage Disorders

The rising prevalence of lysosomal storage disorders (LSDs) is driving significant momentum in the Global Lysosomal Storage Disease Treatment Market, highlighting the growing need for advanced therapeutic solutions. Once considered extremely rare, LSDs are now being identified at higher rates due to improved diagnostic capabilities. Recent Australian government data revealed an LSD diagnosis rate of 1 per 4,800 live births between 2009 and 2020, a figure notably higher than earlier assumptions. This shift reflects the combined impact of expanded newborn screening programs, enhanced genetic testing, and heightened disease awareness among healthcare professionals. Disorders such as Fabry, Gaucher, Pompe, and various mucopolysaccharidoses are now detected earlier, opening the door for timely intervention.

Within this spectrum, Fabry disease has emerged as a particularly prominent condition, accounting for 34% of all LSD diagnoses in Australia. Government-reviewed prevalence data for Gaucher disease indicate an incidence range of 0.45-25 per 100,000 live births, with variations based on region and genetic background. Regions such as North America and Europe tend to report incidence rates toward the higher end of this range, reflecting both a strong diagnostic infrastructure and robust patient registry systems. This growing pool of diagnosed patients has encouraged pharmaceutical companies to increase their investment in targeted therapies, including enzyme replacement therapy (ERT), substrate reduction therapy (SRT), and emerging gene therapy solutions.

The broader recognition of LSDs is not just reshaping patient care but also influencing public health strategies. Governments and advocacy organizations are actively promoting awareness campaigns, funding research initiatives, and facilitating early detection programs. These measures are creating a conducive environment for market growth, as more patients are identified and treated earlier in the disease course. The combination of expanding prevalence rates, patient advocacy efforts, and advancements in therapeutic research is positioning the LSD treatment market for substantial growth during the forecast period.

Key Market Challenges

High Cost of Therapies

The high cost of therapies remains one of the most significant challenges for the Global Lysosomal Storage Disease Treatment Market, substantially limiting patient access, especially in low- and middle-income countries. A recently published German study utilizing data from its public health system reported that mean annual direct costs for home-based enzyme replacement therapy (ERT) across Fabry, Pompe, Gaucher, and MPS I diseases measured approximately USD 395k per year, with nearly 98.5% of these expenses attributable to the drug and administration equipment.

Other government-linked sources confirm similarly daunting figures. For instance, Elosulfase alfa (Vimizim), an ERT for Morquio A syndrome, has treatment costs ranging from USD 2.08 million to USD 6.24 million per year in some contexts. Idursulfase (Elaprase) for Hunter syndrome has been reported at USD 567,412 annually per patient.

High costs are not only financially burdensome for individual patients and families but also strain healthcare systems and insurance providers. Limited or absent reimbursement frameworks for these rare disease therapies leave many without access to necessary treatment. Treatment delays, interrupted regimens, and compromised patient outcomes frequently result when patients cannot afford sustained therapy. The financial inaccessibility undercuts the primary goal of timely intervention in lysosomal disorders, which is critical for preventing irreversible organ damage.

Addressing this challenge requires multi-stakeholder collaboration, including pharmaceutical firms, payers, and policymakers. Strategies such as value-based pricing, expanded insurance coverage, national rare disease funding pools, and targeted patient assistance programs are essential to reduce the affordability gap and enable broader access to these life-saving treatments.

Key Market Trends

Rise of Gene Therapy and RNA-Based Treatments

The Global Lysosomal Storage Disease Treatment Market is experiencing a notable shift with the rising adoption of gene therapy and RNA-based treatments, reshaping the therapeutic landscape for rare metabolic disorders. Gene therapy aims to address the root cause of these diseases by delivering functional copies of defective genes, potentially offering long-term or curative outcomes compared to existing symptomatic treatments. Recent advances in vector technology, such as adeno-associated viral (AAV) vectors, have improved the safety, efficiency, and durability of gene delivery, encouraging more clinical trials targeting conditions like Fabry disease, Gaucher disease, and Pompe disease.

Alongside, RNA-based treatments, including antisense oligonucleotides (ASOs) and mRNA therapies, are gaining traction for their ability to modulate protein expression, correct splicing defects, or enhance enzyme production without altering the genome. These approaches have demonstrated promising efficacy in preclinical and early-stage trials, with several candidates moving toward late-phase development. Growing investments from biopharmaceutical companies and research institutions are accelerating innovation in this space, supported by regulatory incentives such as orphan drug designations and accelerated approval pathways. As manufacturing capabilities and delivery systems improve, gene therapy and RNA-based treatments are poised to expand patient access, reduce treatment burdens, and drive a transformative shift in managing lysosomal storage diseases over the coming decade.

Key Market Players

• Pfizer Inc.
• Takeda Pharmaceutical Company Limited
• Sanofi S.A.
• BioMarin Pharmaceutical Inc.
• Johnson & Johnson (Actelion Pharmaceuticals Ltd)
• Amicus Therapeutics, Inc.
• Alexion Pharmaceuticals, Inc.
• Sigilon Therapeutics, Inc.
• Orphazyme A/S
• Ultragenyx Pharmaceutical Inc.

Report Scope:

In this report, the Global Lysosomal Storage Disease Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Lysosomal Storage Disease Treatment Market, By Treatment Type:

• Enzyme Replacement Therapy
• Substrate Reduction Therapy
• Others

Lysosomal Storage Disease Treatment Market, By Disease Type:

• Gaucher Disease
• Mucopolysaccharidoses
• Pompe Disease
• Fabry Disease
• Others

Lysosomal Storage Disease Treatment Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Lysosomal Storage Disease Treatment Market.

Available Customizations:

Global Lysosomal Storage Disease Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Lysosomal Storage Disease Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Treatment Type [Enzyme Replacement Therapy {Velaglucerase Alfa, Alglucosidase Alfa (Myozyme/Lumizyme), Idursulfase (Elaprase), Imiglucerase (Cerezyme), Others}; Substrate Reduction Therapy, Others]
  • 5.2.2. By Disease Type [Gaucher Disease, Mucopolysaccharidoses, Pompe Disease, Fabry Disease, Others]
  • 5.2.3. By Company (2024)
  • 5.2.4. By Region
• 5.3. Market Map

6. North America Lysosomal Storage Disease Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Treatment Type
  • 6.2.2. By Disease Type
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Lysosomal Storage Disease Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Treatment Type
      • 6.3.1.2.2. By Disease Type
  • 6.3.2. Mexico Lysosomal Storage Disease Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Treatment Type
      • 6.3.2.2.2. By Disease Type
  • 6.3.3. Canada Lysosomal Storage Disease Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Treatment Type
      • 6.3.3.2.2. By Disease Type

7. Europe Lysosomal Storage Disease Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Treatment Type
  • 7.2.2. By Disease Type
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Lysosomal Storage Disease Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Treatment Type
      • 7.3.1.2.2. By Disease Type
  • 7.3.2. Germany Lysosomal Storage Disease Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Treatment Type
      • 7.3.2.2.2. By Disease Type
  • 7.3.3. United Kingdom Lysosomal Storage Disease Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Treatment Type
      • 7.3.3.2.2. By Disease Type
  • 7.3.4. Italy Lysosomal Storage Disease Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Treatment Type
      • 7.3.4.2.2. By Disease Type
  • 7.3.5. Spain Lysosomal Storage Disease Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Treatment Type
      • 7.3.5.2.2. By Disease Type

8. Asia-Pacific Lysosomal Storage Disease Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Treatment Type
  • 8.2.2. By Disease Type
  • 8.2.3. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Lysosomal Storage Disease Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Treatment Type
      • 8.3.1.2.2. By Disease Type
  • 8.3.2. India Lysosomal Storage Disease Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Treatment Type
      • 8.3.2.2.2. By Disease Type
  • 8.3.3. South Korea Lysosomal Storage Disease Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Treatment Type
      • 8.3.3.2.2. By Disease Type
  • 8.3.4. Japan Lysosomal Storage Disease Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Treatment Type
      • 8.3.4.2.2. By Disease Type
  • 8.3.5. Australia Lysosomal Storage Disease Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Treatment Type
      • 8.3.5.2.2. By Disease Type

9. South America Lysosomal Storage Disease Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Treatment Type
  • 9.2.2. By Disease Type
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Lysosomal Storage Disease Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Treatment Type
      • 9.3.1.2.2. By Disease Type
  • 9.3.2. Argentina Lysosomal Storage Disease Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Treatment Type
      • 9.3.2.2.2. By Disease Type
  • 9.3.3. Colombia Lysosomal Storage Disease Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Treatment Type
      • 9.3.3.2.2. By Disease Type

10. Middle East and Africa Lysosomal Storage Disease Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Treatment Type
  • 10.2.2. By Disease Type
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Lysosomal Storage Disease Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Treatment Type
      • 10.3.1.2.2. By Disease Type
  • 10.3.2. Saudi Arabia Lysosomal Storage Disease Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Treatment Type
      • 10.3.2.2.2. By Disease Type
  • 10.3.3. UAE Lysosomal Storage Disease Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Treatment Type
      • 10.3.3.2.2. By Disease Type

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Disruptions: Conflicts, Pandemics and Trade Barriers

14. Porters Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Pfizer Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Recent Developments
  • 15.1.6. Key Personnel Details
  • 15.1.7. SWOT Analysis
• 15.2. Takeda Pharmaceutical Company Limited
• 15.3. Sanofi S.A.
• 15.4. BioMarin Pharmaceutical Inc.
• 15.5. Johnson & Johnson (Actelion Pharmaceuticals Ltd)
• 15.6. Amicus Therapeutics, Inc.
• 15.7. Alexion Pharmaceuticals, Inc.
• 15.8. Sigilon Therapeutics, Inc.
• 15.9. Orphazyme A/S
• 15.10. Ultragenyx Pharmaceutical Inc.

16. Strategic Recommendations

17. About Us & Disclaimer